vs
通用电气医疗（GEHC）与Raymond James Financial（RJF）财务数据对比。点击上方公司名可切换其他公司
通用电气医疗的季度营收约是Raymond James Financial的1.4倍（$5.7B vs $4.2B），Raymond James Financial净利率更高（13.5% vs 10.3%，领先3.2%），通用电气医疗同比增速更快（7.1% vs 3.5%），过去两年通用电气医疗的营收复合增速更高（10.7% vs 7.1%）
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、核磁共振、女性健康筛查、X射线系统）、超声、患者护理解决方案（聚焦远程患者监测、麻醉呼吸护理、心脏病诊断、婴幼儿照护）及制药诊断业务。
雷蒙德詹姆斯金融是美国跨国独立投资银行及金融服务机构，通过旗下子公司为个人、企业及市政主体提供多元金融服务，核心业务覆盖投资与财务规划、投资银行、资产管理等领域，总部位于美国佛罗里达州圣彼得堡。
GEHC vs RJF — 直观对比
营收规模更大
GEHC
是对方的1.4倍
$4.2B
营收增速更快
GEHC
高出3.6%
3.5%
净利率更高
RJF
高出3.2%
10.3%
两年增速更快
GEHC
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.7B | $4.2B |
| 净利润 | $588.0M | $563.0M |
| 毛利率 | 39.7% | — |
| 营业利润率 | 14.5% | — |
| 净利率 | 10.3% | 13.5% |
| 营收同比 | 7.1% | 3.5% |
| 净利润同比 | -18.4% | -6.2% |
| 每股收益（稀释后） | $1.28 | $2.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GEHCRJF
| Q4 25 | $5.7B | $4.2B | ||
| Q3 25 | $5.1B | $4.2B | ||
| Q2 25 | $5.0B | $3.8B | ||
| Q1 25 | $4.8B | $3.8B | ||
| Q4 24 | $5.3B | $4.0B | ||
| Q3 24 | $4.9B | $4.0B | ||
| Q2 24 | $4.8B | $3.8B | ||
| Q1 24 | $4.7B | $3.6B |
净利润GEHCRJF
| Q4 25 | $588.0M | $563.0M | ||
| Q3 25 | $446.0M | $604.0M | ||
| Q2 25 | $486.0M | $436.0M | ||
| Q1 25 | $564.0M | $495.0M | ||
| Q4 24 | $721.0M | $600.0M | ||
| Q3 24 | $470.0M | $602.0M | ||
| Q2 24 | $428.0M | $492.0M | ||
| Q1 24 | $374.0M | $476.0M |
毛利率GEHCRJF
| Q4 25 | 39.7% | — | ||
| Q3 25 | 38.7% | — | ||
| Q2 25 | 39.6% | — | ||
| Q1 25 | 42.1% | — | ||
| Q4 24 | 42.8% | — | ||
| Q3 24 | 41.7% | — | ||
| Q2 24 | 41.4% | — | ||
| Q1 24 | 40.9% | — |
营业利润率GEHCRJF
| Q4 25 | 14.5% | — | ||
| Q3 25 | 12.7% | — | ||
| Q2 25 | 13.1% | 14.7% | ||
| Q1 25 | 13.2% | 17.5% | ||
| Q4 24 | 15.1% | 18.6% | ||
| Q3 24 | 13.9% | — | ||
| Q2 24 | 12.6% | 17.1% | ||
| Q1 24 | 11.6% | 16.7% |
净利率GEHCRJF
| Q4 25 | 10.3% | 13.5% | ||
| Q3 25 | 8.7% | 14.4% | ||
| Q2 25 | 9.7% | 11.3% | ||
| Q1 25 | 11.8% | 12.9% | ||
| Q4 24 | 13.6% | 14.9% | ||
| Q3 24 | 9.7% | 15.0% | ||
| Q2 24 | 8.8% | 13.1% | ||
| Q1 24 | 8.0% | 13.1% |
每股收益（稀释后）GEHCRJF
| Q4 25 | $1.28 | $2.79 | ||
| Q3 25 | $0.98 | $2.96 | ||
| Q2 25 | $1.06 | $2.12 | ||
| Q1 25 | $1.23 | $2.36 | ||
| Q4 24 | $1.58 | $2.86 | ||
| Q3 24 | $1.02 | $2.85 | ||
| Q2 24 | $0.93 | $2.31 | ||
| Q1 24 | $0.81 | $2.22 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.5B | $9.9B |
| 总债务越低越好 | $10.0B | — |
| 股东权益账面价值 | $10.4B | $12.6B |
| 总资产 | $36.9B | $88.8B |
| 负债/权益比越低杠杆越低 | 0.96× | — |
8季度趋势，按日历期对齐
现金及短期投资GEHCRJF
| Q4 25 | $4.5B | $9.9B | ||
| Q3 25 | $4.0B | $11.4B | ||
| Q2 25 | $3.7B | $9.2B | ||
| Q1 25 | $2.5B | $9.7B | ||
| Q4 24 | $2.9B | $10.0B | ||
| Q3 24 | $3.5B | $11.0B | ||
| Q2 24 | $2.0B | $9.1B | ||
| Q1 24 | $2.6B | $10.0B |
总债务GEHCRJF
| Q4 25 | $10.0B | — | ||
| Q3 25 | $10.3B | — | ||
| Q2 25 | $10.3B | — | ||
| Q1 25 | $8.8B | — | ||
| Q4 24 | $9.0B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $9.2B | — | ||
| Q1 24 | $9.3B | — |
股东权益GEHCRJF
| Q4 25 | $10.4B | $12.6B | ||
| Q3 25 | $10.0B | $12.5B | ||
| Q2 25 | $9.7B | $12.3B | ||
| Q1 25 | $9.2B | $12.2B | ||
| Q4 24 | $8.4B | $11.9B | ||
| Q3 24 | $8.3B | $11.7B | ||
| Q2 24 | $7.8B | $11.2B | ||
| Q1 24 | $7.4B | $11.0B |
总资产GEHCRJF
| Q4 25 | $36.9B | $88.8B | ||
| Q3 25 | $36.1B | $88.2B | ||
| Q2 25 | $35.5B | $84.8B | ||
| Q1 25 | $33.6B | $83.1B | ||
| Q4 24 | $33.1B | $82.3B | ||
| Q3 24 | $33.9B | $83.0B | ||
| Q2 24 | $31.9B | $80.6B | ||
| Q1 24 | $32.2B | $81.2B |
负债/权益比GEHCRJF
| Q4 25 | 0.96× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 1.06× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 1.25× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-10.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-56.0M |
| 自由现金流率自由现金流/营收 | — | -1.3% |
| 资本支出强度资本支出/营收 | 2.4% | 1.1% |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | — | $1.4B |
8季度趋势，按日历期对齐
经营现金流GEHCRJF
| Q4 25 | — | $-10.0M | ||
| Q3 25 | — | $796.0M | ||
| Q2 25 | $94.0M | $691.0M | ||
| Q1 25 | $250.0M | $117.0M | ||
| Q4 24 | — | $830.0M | ||
| Q3 24 | — | $510.0M | ||
| Q2 24 | $-119.0M | $711.0M | ||
| Q1 24 | $419.0M | $391.0M |
自由现金流GEHCRJF
| Q4 25 | — | $-56.0M | ||
| Q3 25 | — | $752.0M | ||
| Q2 25 | $8.0M | $634.0M | ||
| Q1 25 | $98.0M | $71.0M | ||
| Q4 24 | — | $789.0M | ||
| Q3 24 | — | $460.0M | ||
| Q2 24 | $-183.0M | $655.0M | ||
| Q1 24 | $274.0M | $342.0M |
自由现金流率GEHCRJF
| Q4 25 | — | -1.3% | ||
| Q3 25 | — | 17.9% | ||
| Q2 25 | 0.2% | 16.5% | ||
| Q1 25 | 2.1% | 1.8% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | — | 11.5% | ||
| Q2 24 | -3.8% | 17.4% | ||
| Q1 24 | 5.9% | 9.4% |
资本支出强度GEHCRJF
| Q4 25 | 2.4% | 1.1% | ||
| Q3 25 | 2.1% | 1.1% | ||
| Q2 25 | 1.7% | 1.5% | ||
| Q1 25 | 3.2% | 1.2% | ||
| Q4 24 | 1.9% | 1.0% | ||
| Q3 24 | 1.9% | 1.2% | ||
| Q2 24 | 1.3% | 1.5% | ||
| Q1 24 | 3.1% | 1.3% |
现金转化率GEHCRJF
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | 1.32× | ||
| Q2 25 | 0.19× | 1.58× | ||
| Q1 25 | 0.44× | 0.24× | ||
| Q4 24 | — | 1.38× | ||
| Q3 24 | — | 0.85× | ||
| Q2 24 | -0.28× | 1.45× | ||
| Q1 24 | 1.12× | 0.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
RJF
暂无分部数据
